Trial Profile
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-Range Exploration Study of Sativex in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary) ; Opioid analgesics
- Indications Cancer pain
- Focus Therapeutic Use
- Acronyms SPRAY
- Sponsors Jazz Pharmaceuticals Inc
- 05 Apr 2012 Results published in the Journal of Pain.
- 05 Apr 2012 Primary endpoint 'Response-rate' has not been met.
- 05 Apr 2012 Primary endpoint 'Numerical-Rating-Scale' has not been met.